Page 7 - Vaccine

After Covishield, new study 'finds' side effects in Covaxin recipients

In observational study on Bharat Biotech's Covaxin recipients, about one-third of participants reported adverse events

12% of India's eligible children received no dose of measles vaccine: Study

Nearly 12 per cent of children in India who are eligible for measles vaccination have received none of the recommended double-dose, signalling a "concerning gap" in immunisation coverage, a new study has found. The findings showed that zero-dose cases were high in the northeastern states, with Nagaland reporting the greatest share at 26 per cent. Tamil Nadu was found to report the lowest at 4.6 per cent. Researchers from the Ministry of Health and Family Welfare and Banaras Hindu University in Varanasi investigated previously overlooked critical aspects of measles vaccination, focusing on zero-doses, partially vaccinated, and those fully immunised. They analysed data of over 43,000 children aged 2-3 years, collected through the National Family Health Survey 2019-21 (NFHS-5). The team found that close to 30 per cent of the eligible children have received only one measles-containing vaccine (MCV1), while about 60 per cent have been fully immunised (MCV2). The findings are published in

Not producing, distributing Covishield since December 2021: Serum Institute

AstraZeneca Covid vaccine row: As of April 30, 2024, over 1.7 billion doses of the Covishield vaccine has been administered in India

SC to hear Serum's plea challenging amendment to IT Act on May 17

With this plea, it also challenged the Bombay High Court's order that dismissed its petition against a 2016 amendment to the Income Tax Act

U-WIN may allow mothers to track and report vaccine side-effects on babies

Similar to the CoWIN portal for covid-19, the government's U-WIN platform registers and tracks routine vaccination and immunisation

Covishield vaccine case: Plea filed in SC seeking probe on AstraZeneca

AstraZeneca, facing a lawsuit in UK for alleged vaccine-related deaths and injuries, has acknowledged that its vaccine can cause Thrombosis with Thrombocytopenia Syndrome (TTS)

AstraZeneca responds to Covishield vaccine concerns: Here's what they said

Regulatory agencies around the world maintain that the risks from the vaccine outweigh the benefits

AstraZeneca's Covishield causes rare blood clot disorder TTS: What is it?

Covishield, a vaccine developed by AstraZeneca and Oxford University and manufactured by the Serum Institute of India, can, in rare instances, lead to TTS

Bharat Biotech co-founder Krishna Ella takes helm as President of IVMA

Ella takes over the presidency from Adar C Poonawalla, who held the post from 2019 to March 2024

Healthcare solution provider Enhanced Innovations launches 'Phloton'

A portable cold chain solution for last-mile vaccine delivery

Bharat Biotech, Bilthoven Biologicals collaborate for oral polio vaccines

Bilthoven Biologicals will produce the vaccines for distribution in India and worldwide

Dr Reddy's partners with Sanofi India to distribute vaccine brands in India

Under the terms of this agreement, Dr Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands, including Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri and Adacel

Bharat Biotech's TB vaccine MTBVAC begins clinical trials in India

The trials will assess the vaccine's safety, immune response, and efficacy in preventing TB in adults and adolescents. MTBVAC has been developed after research spanning over three decades

IVI commences tech transfer of oral cholera vaccine to Biological E

The tech transfer will be completed by 2025 and the vaccine will be manufactured for India and international markets by Biological E

ICMR study shows Covid vaccine not responsible for heart attacks: Govt

Answering a query, Mandaviya said there had been attempts to create misconceptions about Covid-19 vaccines

Takeda injects hope: Dengue vaccine clinical trials set to begin in India

Biological E will increase manufacturing capacity to up to 50 million doses a year, accelerating Takeda's plans to manufacture 100 million doses annually within the decade

Still facing strong headwinds, 2024 sales flat to lower, says Novavax

The company posted a larger-than-expected fourth-quarter loss as revenue lagged analysts' estimates, sending its shares down 26.3% to $4.44 in early trading

Global pharma companies dominate Indian vaccine market: PharmaTrac report

Global pharmaceutical companies hold 60% of value share in India's vaccine market, outperforming domestically manufactured vaccines in terms of revenue

More than half of world's countries will be at high measles risk: WHO

Death rates are higher in poorer countries due to weaker health systems, Crowcroft said, adding that outbreaks and deaths were also a risk for middle and high income countries

British Indian doctor to undertake 'ground-breaking' cancer vaccine trial

The trial will be available for just 44 patients around the world. After the trial finishes, the vaccine will either be licensed for use or if it's successful, a bigger study will be carried out